“NATCO is the first company, after Syngenta, to launch above mentioned CTPR combination products in India. It follows on the heels of indigenously manufactured CTPR formulation 18.5% SC launched by NATCO recently under brand name NATGEN. NATCO has challenged FMC for revocation of their patents for these combination products that are marketed by Syngenta, and the case is pending before the Hon’ble High Court of Delhi”, the company said in a regulatory filing on Tuesday.
At around 12:57 PM, Natco Pharma Ltd is currently trading at Rs619.30 per share up by Rs6.8 or 1.11% from its previous closing of Rs612.50 per share on the BSE.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.